Active, not recruiting • Phase I, II • Stage III, IV • Post-Menopausal • Interventional

The following is imported from ClinicalTrials.gov:

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Brief Summary

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.

Description

Study Design

Eligibility Criteria

Arms and Intervention

• CYT-0851

• CYT-0851 in combination with gemcitabine

• CYT-0851 in combination with capecitabine

• CYT-0851 in combination with rituximab and bendamustine